Literature DB >> 19164237

Effect of patient morphology on dosimetric calculations for internal irradiation as assessed by comparisons of Monte Carlo versus conventional methodologies.

Antigoni Divoli1, Sophie Chiavassa, Ludovic Ferrer, Jacques Barbet, Glenn D Flux, Manuel Bardiès.   

Abstract

UNLABELLED: Dosimetric calculations are performed with an increasing frequency before or after treatment in targeted radionuclide therapy, as well as for radiation protection purposes in diagnostic nuclear medicine. According to the MIRD committee formalism, the mean absorbed dose to a target is given by the product of the cumulated activity and a dose-conversion factor, known as the S factor. Standard S factors have been published for mathematic phantoms and for unit-density spheres. The accuracy of the results from the use of these S factors is questionable, because patient morphology can vary significantly. The aim of this work was to investigate differences between patient-specific dosimetric results obtained using Monte Carlo methodology and results obtained using S factors calculated on standard models.
METHODS: The CT images of 9 patients, who ranged in size, were used. Patient-specific S factors for 131I were calculated with the MCNPX2.5.0 Monte Carlo code using a tool for personalized internal dose assessment, OEDIPE; standard S factors from OLINDA/EXM were compared against the patient-specific S factors. Furthermore, realistic biodistributions and cumulated activities for normal organs and tumors were used, and mean organ- and tumor-absorbed doses calculated with OEDIPE and OLINDA/EXM were compared.
RESULTS: The ratio of the standard and the patient-specific S factors were between 0.49 and 1.84 for a target distant from the source for 4 organs and 2 tumors studied as source and targets. For the case of self-irradiation, the equivalent ratio ranged between 0.45 and 2.47 and between 1.00 and 1.06 when mass correction was applied. Differences in mean absorbed doses were as high as 140% when realistic cumulated activity values were used. These values decreased to less than 26% in all cases studied when mass correction was applied to the self-irradiation given by OLINDA/EXM.
CONCLUSION: Standard S factors can yield mean absorbed doses for normal organs or tumors with a reasonable accuracy (26% for the cases studied) as compared with absorbed doses calculated with Monte Carlo, provided that they have been corrected for mass.

Entities:  

Mesh:

Year:  2009        PMID: 19164237     DOI: 10.2967/jnumed.108.056705

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  19 in total

1.  Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.

Authors:  David M Howard; Kimberlee J Kearfott; Scott J Wilderman; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2011-09-22       Impact factor: 3.099

2.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry.

Authors:  Cecilia Hindorf; Gerhard Glatting; Carlo Chiesa; Ola Lindén; Glenn Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06       Impact factor: 9.236

3.  EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting.

Authors:  M Lassmann; C Chiesa; G Flux; M Bardiès
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-27       Impact factor: 9.236

Review 4.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

5.  OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry.

Authors:  Maxime Chauvin; Damian Borys; Francesca Botta; Pawel Bzowski; Jérémie Dabin; Ana M Denis-Bacelar; Aurélie Desbrée; Nadia Falzone; Boon Quan Lee; Andrea Mairani; Alessandra Malaroda; Gilles Mathieu; Erin McKay; Erick Mora-Ramirez; Andrew P Robinson; David Sarrut; Lara Struelens; Alex Vergara Gil; Manuel Bardiès
Journal:  J Nucl Med       Date:  2020-03-13       Impact factor: 10.057

6.  Deformable torso phantoms of Chinese adults for personalized anatomy modelling.

Authors:  Hongkai Wang; Xiaobang Sun; Tongning Wu; Congsheng Li; Zhonghua Chen; Meiying Liao; Mengci Li; Wen Yan; Hui Huang; Jia Yang; Ziyu Tan; Libo Hui; Yue Liu; Hang Pan; Yue Qu; Zhaofeng Chen; Liwen Tan; Lijuan Yu; Hongcheng Shi; Li Huo; Yanjun Zhang; Xin Tang; Shaoxiang Zhang; Changjian Liu
Journal:  J Anat       Date:  2018-04-16       Impact factor: 2.610

7.  Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient.

Authors:  Abigail E Besemer; Joseph J Grudzinski; Jamey P Weichert; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-10-23       Impact factor: 3.099

8.  Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.

Authors:  Arnaud Dieudonné; Robert F Hobbs; Rachida Lebtahi; Fabien Maurel; Sébastien Baechler; Richard L Wahl; Ariane Boubaker; Dominique Le Guludec; Georges Sgouros; Isabelle Gardin
Journal:  J Nucl Med       Date:  2012-12-18       Impact factor: 10.057

9.  Biodistribution and Radiation Dosimetry of the Enterobacteriaceae-Specific Imaging Probe [(18)F]Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers.

Authors:  Wenjia Zhu; Shaobo Yao; Haiqun Xing; Hui Zhang; Yuan-Chuan Tai; Yingqiang Zhang; Yimin Liu; Yanru Ma; Chenxi Wu; Hongkai Wang; Zibo Li; Zhanhong Wu; Zhaohui Zhu; Fang Li; Li Huo
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

10.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.